Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10065


Purpose:

The purpose of this study is to find out how effective 177Lu -J591 is in the treatment of patients with metastatic, androgen-independent prostate cancer.


Study summary:

To determine the clinical activity of 177Lu -J591 for the treatment of patients with metastatic, androgen-independent prostate cancer. Patients will receive a single dose of J591 (total antibody of 20 mg) consisting of antibody chelated with 177Lu at a dose of 65 or 70 mCi/m2 with a specific activity of 12-15 mCi/mg plus non-radiolabeled antibody.


Criteria:

Inclusion Criteria: - Histologic diagnosis of prostate adenocarcinoma. - Metastatic prostate cancer progressive on imaging studies and/or rising PSA despite adequate medical or surgical castration therapy. - Progressed following discontinuation of anti-androgen therapy, if received. - Serum testosterone < 50 ng/ml Exclusion Criteria: - Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of treatment. - Use of PC-SPES within 4 weeks of treatment. - Use of red blood cell or platelet transfusions within 4 weeks of treatment. - Use of hematopoietic growth factors within 4 weeks of treatment. - Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment. - Bone scan demonstrating confluent lesions involving both axial and appendicular skeleton. - Prior radiation therapy encompassing >25% of skeleton. - Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®). - Active angina pectoris or NY Heart Association Class III-IV. - History of deep vein thrombophlebitis and/or pulmonary embolus within 3 months of study entry. - Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study. - Prior monoclonal antibody therapy with the exception of ProstaScint® - Prior investigational therapy (medications or devices) within 6 weeks of treatment. - Known history of HIV


NCT ID:

NCT00195039


Primary Contact:

Principal Investigator
Scott Tagawa, M.D.
Weill Medical College of Cornell University


Backup Contact:

N/A


Location Contact:

New York, New York 10065
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.